Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

13 Feb 2019

Abstract excerpt

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30760870
DOI: 10.1038/s41375-019-0403-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationPMID 30760870Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma CellsSemantic proximity Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerSemantic proximity Read ↗

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myelomaSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaSemantic proximity Read ↗

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros ProteinsSemantic proximity Read ↗

Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.